{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=30", "query": { "intervention": "ipilimumab", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 640, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T17:26:29.701Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02950766", "title": "NeoVax Plus Ipilimumab in Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "NeoVax", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Patrick Ott, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2019-03-03", "completion_date": "2030-05-30", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-10-29T17:26:29.701Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02950766" }, { "nct_id": "NCT02408861", "title": "Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anal Carcinoma", "HIV Infection", "Kaposi Sarcoma", "Lung Carcinoma", "Metastatic Malignant Solid Neoplasm", "Recurrent Classic Hodgkin Lymphoma", "Refractory Classic Hodgkin Lymphoma", "Unresectable Solid Neoplasm", "HIV-associated Cancers" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2015-10-21", "completion_date": "2024-08-31", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-29T17:26:29.701Z", "location_count": 32, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02408861" }, { "nct_id": "NCT05176483", "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Urothelial Carcinoma (UC)", "Solid Tumor", "Hepatocellular Carcinoma (HCC)", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Clear Cell Renal Cell Carcinoma (ccRCC)", "Non-Clear Cell Renal Cell Carcinoma (nccRCC)", "Drug-Drug Interaction (DDI)" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "DDI Probe Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1394, "start_date": "2021-12-14", "completion_date": "2030-06-28", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-29T17:26:29.701Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176483" }, { "nct_id": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Tumor" ], "interventions": [ { "name": "SQZ-PBMC-HPV", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SQZ Biotechnologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-01-28", "completion_date": "2023-02-09", "has_results": false, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-29T17:26:29.701Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04084951" }, { "nct_id": "NCT01827111", "title": "Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "ABI-007", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Phone Call", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2013-04-25", "completion_date": "2020-09-21", "has_results": true, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-29T17:26:29.701Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01827111" }, { "nct_id": "NCT00861614", "title": "Study of Immunotherapy to Treat Advanced Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 988, "start_date": "2009-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-10-29T17:26:29.701Z", "location_count": 44, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 39 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861614" }, { "nct_id": "NCT02350764", "title": "Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Stage Non-small Cell Lung Cancer" ], "interventions": [ { "name": "nivolumab", "type": "DRUG" }, { "name": "pilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2015-01-20", "completion_date": "2023-09-25", "has_results": true, "last_update_posted_date": "2024-05-29", "last_synced_at": "2026-10-29T17:26:29.701Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02350764" }, { "nct_id": "NCT03873402", "title": "A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 437, "start_date": "2019-06-21", "completion_date": "2027-03-11", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-29T17:26:29.701Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Athens, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Athens", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03873402" }, { "nct_id": "NCT04326257", "title": "Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Nivolumab+Relatlimab", "type": "DRUG" }, { "name": "Nivolumab+Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-05-14", "completion_date": "2024-08-12", "has_results": true, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-29T17:26:29.701Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04326257" }, { "nct_id": "NCT07689175", "title": "Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab (3 mg/kg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-08-21", "completion_date": "2032-10-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-29T17:26:29.701Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07689175" } ] }